P3 Health Partners (PIII) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
14 May, 2026Market opportunity and industry trends
Operates in the $1.2T Medicare Advantage and FFS Medicare market, with 135K total lives and 106K at-risk lives across 6 states, including new entries in Nebraska and North Carolina in 2026.
Medicare Advantage now covers 55% of Medicare beneficiaries, representing 35M people and a structural shift in the market.
Value-based care has created a $4T+ spending gap below projected Medicare trends, demonstrating its impact on bending the cost curve.
Industry consolidation, high Medicare spending, and payor cost pressures are expanding the addressable market and driving demand for cost-controlled platforms.
Business model and operational strategy
Physician-led, enabling providers to transition from fee-for-service to value-based care, improving outcomes and lowering costs.
Fully delegated risk model leverages data, AI-enabled insights, and technology for better clinical outcomes and cost efficiency.
Integrated care model coordinates patient journeys, aligns incentives, and assumes full financial risk for members.
Four operational pillars: patient outcomes, tech-enabled operations, provider enablement, and scalable value creation.
Financial performance and guidance
2026 guidance projects $1.5B–$1.65B in revenue, $190M–$230M medical margin, and $20M–$60M adjusted EBITDA, with a raised midpoint to $40M.
Contract restructuring, bid optimization, and favorable CMS benchmarks are key drivers of improved financial performance.
Operational improvements and payer settlements recognized in early 2026 support positive cash flow and EBITDA.
Latest events from P3 Health Partners
- Revenue up 26% but net loss widened to $102.9M; liquidity risks remain.PIII
Q3 20248 Jul 2026 - Q1 2025 saw revenue and membership decline, improved MLR, and ongoing liquidity risks.PIII
Q1 20258 Jul 2026 - 2025 guidance reaffirmed with profitability expected, despite a deeper 2024 net loss.PIII
Q4 20248 Jul 2026 - Q2 revenue up 15% to $379M, but profitability declined and liquidity risks persist.PIII
Q2 20248 Jul 2026 - All four shareholder proposals were approved, with no questions raised by stockholders.PIII
AGM 20269 Jun 2026 - Q1 2026 delivered $3M net income and $26M adjusted EBITDA, but liquidity risks remain.PIII
Q1 202620 May 2026 - Key votes include director elections, auditor ratification, and approval of new share issuance.PIII
Proxy filing30 Apr 2026 - Shareholders will vote on director elections, auditor ratification, executive pay, and warrant share issuance.PIII
Proxy filing30 Apr 2026 - Board recommends approval of all proposals, including director elections and share issuance.PIII
Proxy filing20 Apr 2026